Headquarters: Waltham, Massachusetts, United States
52 week low:1.81
52 week high:15.22
Next ER:March 8, 2023 Before Market Opens
Top Stories (NERV)
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat central nervous system (CNS) diseases. Minerva's portfolio of compounds includes: Roluperidone (MIN-101) in Phase 3 clinical development for schizophrenia; a potential royalty stream from Seltorexant (MIN-202 or JNJ 42847922), in clinical development for insomnia and major depressive disorder (MDD); and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV."
Talk about Minerva Neurosciences Inc below in comments section below.
Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Most of the datas are collected by our Data Entry and we aim to be as accurate as humanly possible.
Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis